Search Results - "Mao, Yizhe"

Cross-platform comparison of immune signatures in immunotherapy-treated patients with advanced melanoma using a rank-based scoring approach by Mao, Yizhe, Gide, Tuba N, Adegoke, Nurudeen A, Quek, Camelia, Maher, Nigel, Potter, Alison, Patrick, Ellis, Saw, Robyn P M, Thompson, John F, Spillane, Andrew J, Shannon, Kerwin F, Carlino, Matteo S, Lo, Serigne N, Menzies, Alexander M, da Silva, Inês Pires, Long, Georgina V, Scolyer, Richard A, Wilmott, James S

“…Gene expression profiling is increasingly being utilised as a diagnostic, prognostic and predictive tool for managing cancer patients. Single-sample scoring…”
Get full text

Classification of the tumor immune microenvironment and associations with outcomes in patients with metastatic melanoma treated with immunotherapies by Adegoke, Nurudeen A, Gide, Tuba N, Mao, Yizhe, Quek, Camelia, Patrick, Ellis, Carlino, Matteo S, Lo, Serigne N, Menzies, Alexander Maxwell, Pires da Silva, Ines, Vergara, Ismael A, Long, Georgina, Scolyer, Richard A, Wilmott, James S

“…BackgroundTumor microenvironment (TME) characteristics are potential biomarkers of response to immune checkpoint inhibitors in metastatic melanoma. This study…”
Get full text

82 Spatial immunophenotyping of longitudinal metastatic melanoma specimens to identify biomarkers of response and resistance to combination anti-LAG-3 + anti-PD-1-based immunotherapies by Gide, Tuba N, McCutcheon, Ella, Maher, Nigel, Mao, Yizhe, Shang, Ping, Menzies, Alexander M, Silva, Ines Pires da, Wilmott, James S, Scolyer, Richard A, Long, Georgina V

“…BackgroundDual inhibition of the lymphocyte activation gene 3 (LAG-3) and programmed cell death 1 (PD-1) receptors has significantly improved clinical outcomes…”
Get full text

Tissue-based Profiling Techniques to Achieve Precision Medicine in Cancer: Opportunities and Challenges in Melanoma by Gide, Tuba N, Mao, Yizhe, Scolyer, Richard A, Long, Georgina V, Wilmott, James S

“…Immunotherapies targeting the programmed cell death 1 (PD-1) and cytotoxic T lymphocyte antigen 4 (CTLA-4) checkpoint receptors have revolutionised the…”
Get full text

Abstract 5701: Predictive biomarker models of immunotherapy response in patients with metastatic melanoma: genomic, transcriptomic, and immune profiles from the Personalised Immunotherapy Program (PIP) by Gide, Tuba N., Adegoke, Nurudeen A., Mao, Yizhe, Lennox, Monica, Raj, Saurab, Quek, Camelia, Vergara, Ismael A., Maher, Nigel, Potter, Alison, Saw, Robyn P., Thompson, John F., Spillane, Andrew J., Shannon, Kerwin F., Carlino, Matteo S., Gonzalez, Maria, Lo, Serigne N., Menzies, Alexander M., da Silva, Inês Pires, Scolyer, Richard A., Long, Georgina V., Wilmott, James S.

“…Abstract Background: While immune checkpoint inhibitors (ICI) have become the standard-of-care for advanced melanoma patients, only half of treated patients…”
Get full text